Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (11273)	8/17/1999 12:24:00 AM
From: BostonView	Read Replies (2) \| Respond to of 17367

Anyone care to guess the breakup value of this snake-bit crew? Would a top tier player or drug co. pay $400 mil in stock for a boatload of patents, HU1124, mycoprex, and trauma while making Jack a "statistically significant" member of the unemployed? He's got a great future as a mime. BV

To: opalapril who wrote (11273)	8/17/1999 4:21:00 PM
From: John Romeo	Read Replies (2) \| Respond to of 17367

Here they go again, at 4:12pm CNBC announces Xoma down 2 3/4, FDA says may not approve drug. Flip the coin on the percieved press conference, XOMA announces clinical benefit from Meninngo. drug Neuprex. But Noooooooooo. The entire focus is on the negative. Frustrating public perception was the fault of Xoma IMO. They could have used the same wording in the cc sounded more upbeat about the impending meeting and Kept Ellen Martin off the phone with Bloomberg. Would the day be any different?